Search results for " Glucose"

showing 10 items of 566 documents

Glucagon-Like Peptide-1 Receptor Agonists and Dual Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonists in the Trea…

2022

The obesity pandemic is accompanied by increased risk of developing metabolic syndrome (MetS) and related conditions: non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH), type 2 diabetes mellitus (T2DM) and cardiovascular (CV) disease (CVD). Lifestyle, as well as an imbalance of energy intake/expenditure, genetic predisposition, and epigenetics could lead to a dysmetabolic milieu, which is the cornerstone for the development of cardiometabolic complications. Glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) and dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 RAs promote positive effects on most components of the “ cardiometabolic continuum” an…

Metabolic SyndromePharmacologyglucagon-like peptide-1 receptor agonists glucose-dependent insulinotropic polypeptide receptor agonists non-alcoholic fatty liver disease obesity prediabetes tirzepatide type 2 diabetes mellitusGlucagon-Like Peptide-1 ReceptorPrediabetic StateGlucoseDiabetes Mellitus Type 2Non-alcoholic Fatty Liver DiseaseGlucagon-Like Peptide 1HumansPharmacology (medical)ObesityPeptidesCardiology and Cardiovascular MedicineJournal of Cardiovascular Pharmacology and Therapeutics
researchProduct

Diagnostic use of fructosamine assay in the control of type II diabetes mellitus.

1988

In an attempt to evaluate the usefulness of fructosamine assay in monitoring type II diabetes, 142 diabetic patients were investigated. Fructosamine values were found to be higher in patients on insulin treatment than on oral hypoglycemic agents. In order to evaluate the metabolic control by using the correlated variations of F, Gm and HbAlc, the patients were subdivided into many control classes: mean values of fructosamine were higher in poorly controlled patients. Fructosamine however correlated better with glycemia in patients with recent variations in metabolic state than HbAlc. It was concluded that fructosamine is a good index for short-term metabolic control, and if used in an integ…

Metabolic stateAdultBlood GlucoseMalemedicine.medical_specialtyEndocrinology Diabetes and Metabolismmedicine.medical_treatmentGastroenterologyType ii diabeteschemistry.chemical_compoundEndocrinologyPhenforminReference ValuesDiabetes mellitusInternal medicineGlyburideInternal MedicineMedicineHumansInsulinIn patientGlycated Hemoglobinbusiness.industryInsulinHexosaminesGeneral MedicineMiddle Agedmedicine.diseaseFructosamineEndocrinologychemistryDiabetes Mellitus Type 2Metabolic control analysisOral hypoglycemic agentsFructosamineFemalebusinessActa diabetologica latina
researchProduct

Mitochondrial dynamics in type 2 diabetes: Pathophysiological implications

2017

Mitochondria play a key role in maintaining cellular metabolic homeostasis. These organelles have a high plasticity and are involved in dynamic processes such as mitochondrial fusion and fission, mitophagy and mitochondrial biogenesis. Type 2 diabetes is characterised by mitochondrial dysfunction, high production of reactive oxygen species (ROS) and low levels of ATP. Mitochondrial fusion is modulated by different proteins, including mitofusin-1 (MFN1), mitofusin-2 (MFN2) and optic atrophy (OPA-1), while fission is controlled by mitochondrial fission 1 (FIS1), dynamin-related protein 1 (DRP1) and mitochondrial fission factor (MFF). PARKIN and (PTEN)-induced putative kinase 1 (PINK1) partici…

MiD51 mitochondrial dynamics proteins of 51 kDaΔΨm mitochondrial membrane potential0301 basic medicineMitochondrial fission factorClinical BiochemistryMitochondrial DegradationMFN2Review ArticleTXNIP thioredoxin interacting proteinMitochondrial DynamicsBiochemistryAdenosine TriphosphateGRP78 78 kDa glucose-regulated proteinMFF mitochondrial fission factorMFN2 mitofusin 2TRX2 thioredoxin 2Redox biologylcsh:QH301-705.5NF-κB nuclear factor kappa Blcsh:R5-920MitophagyType 2 diabetesDRP1 dynamin-related protein 1FIS1 fission protein 1BNIP3 BCL2/adenovirus E1B 19 kDa interacting protein 3MitochondriaOPA1 optic atrophy 1SIRT1/3 sirtuin 1/3Biochemistrymitochondrial fusionTGF-β1 transforming growth factor-β1Mitochondrial fissionOMM outer mitochondrial membranelcsh:Medicine (General)MiD49 mitochondrial dynamics proteins of 49Nox 4 NADPH oxidase-4IMM inner mitochondrial membraneFIS1ATF6 activating transcription factor 6PINK1mTOR mammalian target of rapamycinCHOP C/EBP homologous proteinBiologymdivi-1 mitochondrial division inhibitor-1Mitochondrial Proteins03 medical and health sciencesROS reactive oxygen speciessXBP1 spliced X-box binding protein 1UCP-1 uncoupling protein-1MFN1 mitofusin 1SOD superoxide dismutaseLC3 1 A/1B-light chain 3HumansPINK1 (PTEN)-induced putative kinase 1S3 15-OxospiramilactoneOrganic ChemistrymtDNA mitochondrial DNAAMPK AMP-activated protein kinase030104 developmental biologyDiabetes Mellitus Type 2Mitochondrial biogenesislcsh:Biology (General)Oxidative stressp38 MAPK p38 mitogen-activated protein kinasep62/SQSTM1 ubiquitin and sequestosome-1Reactive Oxygen SpeciesRedox Biology
researchProduct

Defective carbohydrate metabolism in multiple sclerosis

2015

La esclerosis múltiple (EM) es una enfermedad crónica del sistema nervioso central (SNC) en el que episodios repetidos de inflamación (bortes), dan lugar a inflamación que conduce a la interrupción de la vaina de mielina por daños producidos en la misma. Junto a este fenómeno de inflación focal, existe una inflamación difusa en el SNC, que unida a la anterior, dará lugar a que aparezca un proceso de neurodegeneración, que será el responsable último de la afectación axonal y neuronal difusa que es la que va a condicionar la discapacidad en los pacientes afectos de EM. La enfermedad es una causa importante de discapacidad neurológica y de disfunción neurológica en adultos jóvenes que afecta a…

Multiple Sclerosisneurodegenerative diseasebrain glucose metabolismIntermediate MetabolismMolecular Neurosciencerelapsing-remitting multiple sclerosiscerebrospinal fluid
researchProduct

Fourth‐generation glucose sensors composed of copper nanostructures for diabetes management: A critical review

2022

Abstract More than five decades have been invested in understanding glucose biosensors. Yet, this immensely versatile field has continued to gain attention from the scientific world to better understand and diagnose diabetes. However, such extensive work done to improve glucose sensing devices has still not yielded desirable results. Drawbacks like the necessity of the invasive finger‐pricking step and the lack of optimization of diagnostic interventions still need to be considered to improve the testing process of diabetic patients. To upgrade the glucose‐sensing devices and reduce the number of intermediary steps during glucose measurement, fourth‐generation glucose sensors (FGGS) have be…

NanostructureMaterials sciencediabetes managementelectrode materialsBiomedical EngineeringReviewsPharmaceutical Sciencechemistry.chemical_elementEarly detectionhybrid copper nanostructuresNanotechnologyRM1-950ReviewB800Chemical engineeringnonenzymatic glucose sensorsDiabetes managementFourth generationGlucose sensorsearly detectionElectrode materialCopperchemistryTP155-156Therapeutics. PharmacologyTP248.13-248.65BiotechnologyBioengineering & Translational Medicine
researchProduct

The usefulness of Olanzapine plasma concentrations in monitoring treatment efficacy and metabolic disturbances in first-episode psychosis

2021

Introduction: The role of Olanzapine therapeutic drug monitoring is controversial. The present study explores the associations of Olanzapine plasma concentrations with clinical response and metabolic side effects in first episode psychosis (FEP) after 2 months of treatment. Methods: Forty-seven patients were included. Improvement in clinical symptomatology was assessed using the PANSS. Metabolic assessment included weight, blood pressure, waist circumference, blood glucose, total cholesterol, high-density lipoprotein, low-density lipoprotein, and triglycerides. Results: The Olanzapine plasma concentrations after 2 months of treatment were positively correlated with weight gain (r = 0.49, p …

OlanzapineAdultBlood GlucoseMalemedicine.medical_specialtyFarmacologiaWaistBlood PressureWeight GainGastroenterology03 medical and health sciences0302 clinical medicinePharmacokineticsInternal medicinemedicineHumansPharmacologyValproic Acidmedicine.diagnostic_testbusiness.industrySmokingMiddle Aged030227 psychiatryBlood pressureTreatment OutcomePsychotic DisordersTherapeutic drug monitoringOlanzapineFemalemedicine.symptomDrug MonitoringbusinessWeight gain030217 neurology & neurosurgeryMedicamentsLipoproteinmedicine.drugAntipsychotic Agents
researchProduct

P4570Prognostic interest of HbA1c and plasma glucose assessment on one-year mortality in non-diabetic patients after acute myocardial infarction

2019

Abstract Background The usefulness of the combined assessment of HbA1c and plasma glucose (PG) in acute myocardial infarction (AMI) in nondiabetic patients remains unclear. Purpose In a large observational study, we aimed to identify the prognostic values of these biomarkers regarding one-year all-cause mortality in nondiabetic patients after AMI. Methods From the “obseRvatoire des Infarctus de Côte d'Or” (RICO) survey database, we included all consecutive nondiabetic patients with AMI (n=6617) from May 2001 to December 2016. Exclusion criteria were: admission known or unknown diabetes, in-hospital death. The primary endpoint was all-cause one-year mortality. The secondary endpoints were: M…

One year mortalityPlasma glucosemedicine.medical_specialtybusiness.industryInternal medicinemedicineCardiologyMyocardial infarctionCardiology and Cardiovascular Medicinemedicine.diseasebusinessNon diabeticEuropean Heart Journal
researchProduct

The automated pancreas: A review of technologies and clinical practice

2021

Insulin pumps and glucose sensors are effective in improving diabetes therapy and reducing acute complications. The combination of both devices using an algorithm-driven interoperable controller makes automated insulin delivery (AID) systems possible. Many AID systems have been tested in clinical trials and have proven safety and effectiveness. However, currently, none of these systems are available for routine use in children younger than 6 years in Europe. For continued use, both users and prescribers must have sound knowledge of the features of the individual AID systems. Presently, all systems require various user interactions (e.g. meal announcements) because fully automated systems ar…

Pancreas ArtificialInsulin pumpTelemedicinebusiness.industryBlood Glucose Self-MonitoringEndocrinology Diabetes and MetabolismInteroperabilityHCL; artificial pancreas; automated delivery; closed loop; insulin; insulin AIDCloud computingDiabetes TherapyArtificial pancreasClinical trialInsulin Infusion SystemsEndocrinologyRisk analysis (engineering)Diabetes MellitusInternal MedicineHumansMedicineMetric (unit)ChildbusinessDiabetes, Obesity and Metabolism
researchProduct

Argan oil prevents down-regulation induced by endotoxin on liver fatty acid oxidation and gluconeogenesis and on peroxisome proliferator-activated re…

2015

In patients with sepsis, liver metabolism and its capacity to provide other organs with energetic substrates are impaired. This and many other pathophysiological changes seen in human patients are reproduced in mice injected with purified endotoxin (lipopolysaccharide, LPS). In the present study, down-regulation of genes involved in hepatic fatty acid oxidation (FAOx) and gluconeogenesis in mice exposed to LPS was challenged by nutritional intervention with Argan oil. Mice given a standard chow supplemented or not with either 6% (w/w) Argan oil (AO) or 6% (w/w) olive oil (OO) prior to exposure to LPS were explored for liver gene expressions assessed by mRNA transcript levels and/or enzyme a…

Peroxisome proliferator-activated receptor gammamedicine.medical_specialtyOO olive oilResearch paper[SDV]Life Sciences [q-bio]Peroxisome proliferator-activated receptorBiologyBiochemistryNuclear receptor 30lcsh:BiochemistryEstrogen-related receptorEstrogen-related receptor alphaInternal medicineACADS acyl CoA dehydrogenase short-chainACADL acyl CoA dehydrogenase long-chainmedicinePGC-1α peroxisome proliferator-activated receptor γ coactivator-1αlcsh:QD415-436ReceptorBeta oxidationHNF-4α hepatic nuclear factor-4αchemistry.chemical_classificationACADM acyl CoA dehydrogenase medium-chainPPARα peroxisome proliferator-activated receptor αERRα estrogen related receptor α[ SDV ] Life Sciences [q-bio]PEPCK phospoenolpyruvate carboxykinaseGluconeogenesisBeta-oxidationGlut4 glucose transporter 4[SDV] Life Sciences [q-bio]G6PH glucose-6-phosphataseEndocrinologyGlut2 glucose transporter 2chemistryNuclear receptorArgan oilAO Argan oilNuclear receptorACOX1 acyl-CoA oxidase 1CoactivatorLPS lipopolysaccharidePeroxisome proliferator-activated receptor alpha
researchProduct

The Emerging Role of Dual GLP-1 and GIP Receptor Agonists in Glycemic Management and Cardiovascular Risk Reduction

2022

The incretin pathway is a self-regulating feedback system connecting the gut with the brain, pancreas, and liver. Its predominant action is on the postprandial glucose levels, with extraglycemic effects on fat metabolism and endovascular function. Of the two main incretin hormones released with food ingestion, the actions of glucagon-like peptide-1 (GLP-1) have been exploited for therapeutic benefit. However, little attention has been paid to glucose-dependent insulinotropic polypeptide (GIP) until the recent experimental introduction of dual agonists, or "twincretins". Interestingly, simultaneous activation of both receptors is not only replicative of normal physiology, it seems to be an i…

PharmacologyInternal Medicineglucagon-like peptide-1 glucose-dependent insulinotropic polypeptide incretins type 2 diabetesDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy
researchProduct